This site is intended for healthcare professionals

Tezepelumab BLA is submitted to the FDA to treat severe asthma. Amgen + AstraZeneca

Read time: 1 mins
Last updated:28th Jun 2021
Published:11th May 2021
Amgen has announced its partner AstraZeneca submitted a Biologics License Application (BLA) to the FDA for tezepelumab, a potential first-in-class medicine in severe asthma.
Condition: Asthma ( Severe)
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest